Endomatic
Endovascular Left Atrial Appendage Closure Device
Health Tech & Life Sciences
Private
Company Overview
Snapshot
Founded in June 2018 by Boaz Schwarz, Endomatic operates with 1–10 employees. The company has raised $1 million across 4 funding rounds from 1 investor.
Business overview
Endomatic is a Health Tech & Life Sciences company specializing in the development of an endovascular Left Atrial Appendage (LAA) closure device designed to prevent strokes. The company's core technology aims to address the risk of device-related thrombus (DRT), a significant concern in current LAA occlusion procedures, by utilizing a patented non-thrombogenic approach. Endomatic serves the healthcare market, specifically targeting interventional cardiologists and electrophysiologists, and operates within the medical devices sector.
Log in to access full profile ›Company Intelligence Q&A
- What is Endomatic's primary focus?
- Endomatic is focused on developing an endovascular Left Atrial Appendage (LAA) closure device to prevent strokes, particularly in patients with Atrial Fibrillation.
- Who founded Endomatic?
- Endomatic was founded by Boaz Schwarz in June 2018.
- What is the key innovation of Endomatic's technology?
- Endomatic's patented technology aims to eliminate the risk of device-related thrombus (DRT), a common concern with existing LAA closure devices, due to its non-thrombogenic nature.